Vivita Technologies

ViVita Technologies, Inc. is a medical device company focused on developing innovative solutions in tissue engineering and regenerative medicine. The company's core technology, known as the SPEAR Process, is a patented platform that removes immunological barriers from animal-derived tissues. This process results in the creation of the BARE Patch, an immune-compatible biomaterial that provides a blueprint for regeneration when used in human patients. ViVita's technology aims to address the critical shortage of donor organs and tissues by generating off-the-shelf tissue and organ replacements that eliminate the need for long-term medication and repeat transplants.

The company's initial focus is on the heart valve market, where its technology could significantly improve upon existing biological valve replacements. Current biological valves, made from cow or pig tissues, typically last only about 10 years in adults due to immune system rejection. ViVita's chemical platform process extracts antigens from animal tissue to create a scaffold that the human immune system won't reject, potentially extending the lifespan of biological valves to 15-20 years. This advancement could make biological valves a more attractive option compared to mechanical valves, which require patients to take blood thinners for life.

ViVita's technology has broader applications beyond heart valves. The company plans to develop a product pipeline that includes solutions for heart muscle, small vessels, bone, liver, and cartilage. By removing antigens from animal-derived tissues, ViVita's process could potentially be applied to a wide range of tissue and organ replacement products, offering a promising solution to the organ shortage crisis.